SCHEMBL4512468

SCHEMBL4512468

COC(=O)c1cc2cc(C)[nH]c2cc1OC

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 1/20 0.46
DYRK1B Q9Y463 1/20 0.46
GAA P10253 2/20 0.45
ALDH1A1 P00352 7/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
PKM P14618 1/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
KDM4E B2RXH2 7/20 0.42
AXL P30530 1/20 0.42
MAPT P10636 5/20 0.42
POLB P06746 3/20 0.42
HPGD P15428 2/20 0.42
IRAK4 Q9NWZ3 1/20 0.42
HSD17B10 Q99714 1/20 0.41
LMNA P02545 2/20 0.40
KDR P35968 1/20 0.40
EHMT2 Q96KQ7 1/20 0.40
HTT P42858 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31336180 1.00 DYRK1A (0.46) DYRK1ADYRK1BGAAALDH1A1SMN1; SMN2
SCHEMBL4505479 0.86 ALDH1A1 (0.54) DYRK1ADYRK1BGAAALDH1A1SMN1; SMN2
SCHEMBL4497201 0.83 MAOA (0.43) GAAALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL10319865 0.78 DYRK1A (0.61) DYRK1ADYRK1BGAAALDH1A1KDM4E
SCHEMBL266817 0.77 EHMT2 (0.62) DYRK1ADYRK1BALDH1A1SMN1; SMN2PKM
SCHEMBL7899516 0.76 GRIN2D (0.63) DYRK1ADYRK1BGAAALDH1A1SMN1; SMN2
SCHEMBL6582728 0.75 KDM4E (0.67) GAAALDH1A1KMT2AKDM4EMAPT
SCHEMBL27980556 0.75 MAPK14 (0.51) GAAMEN1KMT2AMAPTPOLB
SCHEMBL29615887 0.74 AXL (0.56) GAASMN1; SMN2MEN1KMT2AKDM4E
SCHEMBL22836173 0.74 AXL (0.56) GAASMN1; SMN2MEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4720038-A1 (HETERO)ARYL-CARBONYL-HETEROBICYCLIC COMPOUNDS AS INHIBITORS OF PMS2 FOR CANCER AND DEGENERATIVE ILLNESSES Neophore Limited (GB) 2026-04-08 EP disclosed
WO-2024246496-A1 (HETERO)ARYL-CARBONYL-HETEROBICYCLIC COMPOUNDS AS INHIBITORS OF PMS2 FOR CANCER AND DEGENERATIVE ILLNESSES Neophore Limited (GB) 2024-12-05 WO disclosed
US-7488744-B2 Indole-type derivatives as inhibitors of p38 kinase SCIOS, INC. (US) 2009-02-10 US disclosed
US-7488744-B2 Indole-type derivatives as inhibitors of p38 kinase SCIOS, INC. (US) 2009-02-10 US disclosed
US-7488744-B2 Indole-type derivatives as inhibitors of p38 kinase SCIOS, INC. (US) 2009-02-10 US disclosed
US-20070232617-A1 INDOLE-TYPE DERIVATIVES AS INHIBITORS OF P38 KINASE SCIOS, INC. (US) 2007-10-04 US disclosed
US-20070232617-A1 INDOLE-TYPE DERIVATIVES AS INHIBITORS OF P38 KINASE SCIOS, INC. (US) 2007-10-04 US disclosed
US-20070232617-A1 INDOLE-TYPE DERIVATIVES AS INHIBITORS OF P38 KINASE SCIOS, INC. (US) 2007-10-04 US disclosed
US-7220763-B2 Indole-type derivatives as inhibitors of p38 kinase SCIOS, INC. (US) 2007-05-22 US disclosed
US-7220763-B2 Indole-type derivatives as inhibitors of p38 kinase SCIOS, INC. (US) 2007-05-22 US disclosed
US-7220763-B2 Indole-type derivatives as inhibitors of p38 kinase SCIOS, INC. (US) 2007-05-22 US disclosed
EP-1545528-A4 INDOLE-TYPE DERIVATIVES AS INHIBITORS OF P38 KINASE SCIOS INC (US) 2006-07-26 EP disclosed
EP-1545528-A2 INDOLE-TYPE DERIVATIVES AS INHIBITORS OF P38 KINASE SCIOS INC. (US) 2005-06-29 EP disclosed
US-20040142940-A1 Indole-type derivatives as inhibitors of p38 kinase SCIOS, INC. 2004-07-22 US disclosed
WO-2004022712-A2 INDOLE-TYPE DERIVATIVES AS INHIBITORS OF p38 KINASE SCIOS INC. (US) 2004-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040142940-A1 Indole-type derivatives as inhibitors of p38 kinase MAPK1, MAPKAPK2, MAPK4 DYRK1A 304/4885DYRK1B 340/4885GAA 4841/4885
US-20070232617-A1 INDOLE-TYPE DERIVATIVES AS INHIBITORS OF P38 KINASE MAPK1, MAPKAPK2, MAPKAPK5 DYRK1A 378/4885DYRK1B 435/4885GAA 4776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.